SEROXAT AND OTHER SSRIs

News and Views on the SSRI Group of Drugs

  • THE LIES ABOUT SEROXAT/PAXIL AND OTHER SSRIs

  • STOP the Lies: Join the Cause: Click pic below

  • Enter your email address to subscribe to this blog and receive notifications of new posts by email.

    Join 7 other followers

  • Monthly Archive showing # of posts

Posts Tagged ‘Justice’

2011 SSRI Related Deaths

Posted by shutah on February 20, 2011

It’s Sunday, 20 February 2011

51 days into the year

43 incidents listed already

 

SSRI Related Deaths 2011

 

Does anyone care?

HOW LONG MUST THIS LIST GET BEFORE GOVERNMENTS AND PHARMACEUTICAL COMPANIES ACKNOWLEDGE THE GLOBAL PROBLEMS SURROUNDING SSRIs?

IT’S NOT ABOUT MONEY, STOCKS, SHARES!

IT’S ABOUT HUMAN LIFE

STOP * LOOK * LISTEN

DO SOMETHING!

 

 


Advertisements

Posted in GlaxoSmithKline, GSK, MHRA, SSRIs | Tagged: , , , , , , , , , , , , | Leave a Comment »

GSK gives in – Last-minute deal in Avandia suit

Posted by shutah on January 31, 2011

A federal court in Philadelphia was all set to hear a liability lawsuit against GlaxoSmithKline today, but an 11th-hour settlement took that case right off the docket. GSK made a deal with the family of Avandia patient James Burford to resolve claims that the diabetes drug caused his fatal heart attack. GSK recently took a $3.5 billion charge for legal expenses, including new Avandia litigation filed in the U.S.

The settlement lets GSK avoid the risk of a jury trial, Matrix Corporate Capital analyst Navid Malik told Bloomberg. Investors had worried that a trial “could lead to substantial punitive damages,” Malik said. “GSK needs to successfully settle as many of these cases as possible.”

Two other suits brought by the same plaintiff attorneys were also settled. “GSK has resolved the Burford case scheduled for trial today in the U.S. District Court in Philadelphia, and all cases represented by attorneys Joseph Zonies and Thomas Cartmell,” GSK said in a statement, which also emphasizes that, “GSK continues to stand behind the safety and efficacy of Avandia when used appropriately and according to its label.”

Avandia’s safety, particularly its potential link to heart attack risks, has been under debate for several years, and GSK has already resolved some 10,000 liability suits with a $460 million settlement. In September, European regulators banned Avandia, saying its risks outweighed its benefits. The FDA stopped short of withdrawing the drug, but sharply restricted its use, and GSK agreed to stop promoting it. About 2,000 more lawsuits remain outstanding.

This SUCKS!!!  Not for the Claimants, I’m thrilled for them.  But GSK have ‘settled’ the case, thereby allowing them to walk away from their responsibilities by not having to testify in Court.

Their statement … “GSK continues to stand behind the safety and efficacy of Avandia ….” shows them to be lily-livered, cold-hearted bureaucrats with a seemingly bottomless well of money to throw about.  I’ll bet GSK doesn’t have the balls to ‘fess up to their errors when it comes to the SSRI drugs they ‘peddle’ around the World!!!  Boo, Hiss GSK!!!!

Posted in GlaxoSmithKline | Tagged: , , , , , , , | Leave a Comment »

Legal Action Delayed

Posted by shutah on January 30, 2011

End to epilepsy drug action delayed

By Cathy Gordon, PA 28 January 2011

 

A move to discontinue legal action brought by families who blame an epilepsy drug for causing defects in their children suffered a delay today.

Claims by more than 150 families were expected to be formally discontinued at a hearing before a judge at the High Court in London.

But Mr Justice Eady was told that a “difficulty” had arisen which meant that the proceedings would have to be adjourned.

Lawyers representing the families had earlier announced they had been forced to abandon the trial of the action following the withdrawal of legal aid.

The Legal Services Commission (LSC) said in November it was no longer funding an action against the makers of sodium valproate, a drug used to prevent epileptic seizures.

Claimants allege that the drug, also known as Epilim, caused a range of birth defects, including spina bifida, damage to the heart, learning difficulties, cleft palate and deformities of the hands and feet.

They have been pursuing a legal action for damages against manufacturer sanofi-aventis, claiming there were inadequate warnings about possible harm in the 1990s.

The firm has denied the claims, saying it has always provided appropriate precautions and warnings on the risks associated with possible side-effects of the medicine.

The plan for today was for lawyers for the families to advise the judge that the case against the manufacturers must be discontinued because continuing without legal aid funding would place their clients at “too great a financial risk”.

But the proceedings were adjourned for clarification to be sought relating to the terms of a proposed final order in the case.

Mr Justice Eady heard that the defendant would be taking instructions from representatives in France relating to one part of the order – that concerning the circumstances in which it would seek to enforce costs at any time in the future.

The court heard that there may have to be further consultation with all of the claimants by their lawyers to explain the situation to them with regard to the costs implications – a process which could take three months.

A further hearing is now expected to take place at the High Court in May.

Announcing the move to discontinue recently, solicitors Irwin Mitchell said their clients were “devastated” that their case would never be heard in court after six years of preparation for trial.

Despite the fact that the legal action has had to be dropped, families have vowed to continue their campaign.

A Legal Services Commission spokesman said: “Following advice from counsel, the Legal Services Commission has withdrawn legal aid funding for the multi-party action claim against the makers of the drug Epilim.

“Before making the decision, LSC had to await the exchange of evidence and the provision of comprehensive opinions from counsel – this process was only completed by the solicitors in late October.

“The claimants then exercised their right to appeal to a panel of lawyers who are independent of the LSC. This panel upheld the decision to withdraw funding.

“We have great sympathy with those who claim to have had adverse effects in connection with this medication, but our funding decisions must always be based on solid legal grounds.”

 

Posted in Blogroll, Health | Tagged: , | 2 Comments »